PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS Jan 12, 2022
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus Nov 24, 2021
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 Sep 13, 2021
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis Aug 4, 2021
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease May 25, 2021
